Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of health-care revenue-cycle-management specialist Accretive Health
So what: After falling 15% over the first 11 days of the month, the stock has now bounced more than 55% since. Investors were initially disappointed with Accretive's weaker-than-expected third-quarter results, but positive notes from a few Wall Street analysts shortly thereafter -- including from its underwriters JPMorgan Chase
Now what: I love making cheap bets on companies with a long history of success, and Accretive just doesn't fit that profile right now. With today's double-digit pop, the shares should close out the trading day sporting a rather lofty 30-plus forward P/E. While that multiple could actually turn out to be cheap over time -- analysts expect 30% profit growth in each of the next five years -- the company is simply too young to call it a prudent investment.
Interested in more info on Accretive? Add it to your watchlist.
Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Try any of our Foolish newsletter services free for 30 days. True to its name, The Motley Fool is made up of a motley assortment of writers and analysts, each with a unique perspective; sometimes we agree, sometimes we disagree, but we all believe in the power of learning from each other through our Foolish community. The Fool's disclosure policy always gets a perfect score.